An international assessment of ovarian cancer incidence and mortality

Lowe, Kimberly A.; Chia, Victoria; Taylor, Aliki; O’Malley, Cynthia D.; Kelsh, Michael A.; Mohamed, Muhima; Mowat, Fionna; Goff, Barbara A.

doi:10.1016/j.ygyno.2013.03.026

Cited by 201 publications

(158 citation statements)

References 18 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…However, the incidence rates of ovary cancer in Northern Europe and the United States showed some decline trend recently, especially among younger women Lowe et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Time Trends of Ovarian Cancer Incidence in China

Wang¹,

Liu²,

Zheng³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

The aim of this study was to examine the trend of ovary cancer incidence from 1999 to 2010 in China and predict the burden up to 2020. Crude incidence, age specific incidence and age-adjusted incidence rates were calculated. Joinpoint regression was performed to obtain estimated annual percentages and Bayesian age-periodcohort modeling was used to predict the incidence rate until the year 2020. In China, the crude rate of ovary cancer was 7.91/100,000 and the age-adjusted rate was 5.35/100,000 overall during period 1999-2010. The rates in urban regions were higher than in rural regions. A significant rising trend during 1999-2006 was followed by a drop during 2006-2010 in age-adjusted rates for urban females. In contrast, constant rise was observed in rural women. The decrease in ovary cancer of urban areas tended to be restricted to women aged 50 years and younger. In contrast, increases of ovary cancer in rural areas appeared in virtually all age groups. Although the age-adjusted incidence rate for ovary cancer was predicted to be reduced after year 2011, the crude rate was likely to be relative stable up to 2020. The burden of ovary cancer in China will continue to be relative stable due to the aging population.

show abstract

“…However, the incidence rates of ovary cancer in Northern Europe and the United States showed some decline trend recently, especially among younger women Lowe et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Time Trends of Ovarian Cancer Incidence in China

Wang¹,

Liu²,

Zheng³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…The rate of ovarian cancer in our population was low when compared to the rates reported from developed countries including the USA (9.2) and the UK (12.7) (Forman et al, 2013). These geographical differences may be contributed to genetic factors of cultural habits and lifestyle practices including reproductive behaviors in various regions of the world (Lowe et al, 2013).…”

Section: Discussionmentioning

confidence: 99%

Epidemiology of Female Reproductive Cancers in Iran: Results of the Gholestan Population-Based Cancer Registry

Taheri¹,

Fazel²,

Mahmoodzadeh³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Malignancies of the female reproductive tract are estimated to be the third most common group of cancers in women. Objectives: We here aimed to present their epidemiological features in Golestan province located in Northeast of Iran. Materials and Methods: Data on primary female reproductive cancers diagnosed between 2004-2010 were obtained from Golestan Population-based Cancer Registry (GPCR). CanReg-4 and SPSS software were used for data entry and analysis. Age standardized incidence rates (ASR) (per 100,000 person-years) were calculated using the world standard population. Poisson regression analysis was used to compare incidence rates. P-values of less than 0.05 were considered as significant. Results: A total of 6,064 cancer cases were registered in Golestan females in the GPCR during 2004-2010, of which 652 cases (11%) were female reproductive cancers. Cancers of the ovary (ASR=6.03) and cervix (ASR=4.97) were the most common. We found significant higher rates in females living in cities than in villages. Our results showed a rapid increase in age specific incidence rates of female reproductive cancers at the age of 30 years. Conclusions: We found significant higher rates of female reproductive cancers among residents of cities than villages. Differences in the prevalence of risk factors including reproductive behavior between the two populations may partly explain such diversity. Our results also showed a rapid increase in incidence rates of these cancers in young age females. Further studies are warranted to determine risk factors of female reproductive cancers in our population.

show abstract

“…OC is most frequently diagnosed in patients above the age of 65 years [Yancik, 1993; Lowe et al., 2013]. However, the average age of onset is lower in patients who carry an OC predisposing germline aberration [Prat et al., 2005; Weissman, et al., 2012].…”

Section: Introductionmentioning

confidence: 99%

NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas

et al. 2016

View full text Add to dashboard Cite

With the recent introduction of Poly(ADP‐ribose) polymerase inhibitors, a promising novel therapy has become available for ovarian carcinoma (OC) patients with inactivating BRCA1 or BRCA2 mutations in their tumor. To select patients who may benefit from these treatments, assessment of the mutation status of BRCA1 and BRCA2 in the tumor is required. For reliable evaluation of germline and somatic mutations in these genes in DNA derived from formalin‐fixed, paraffin‐embedded (FFPE) tissue, we have developed a single‐molecule molecular inversion probe (smMIP)‐based targeted next‐generation sequencing (NGS) approach. Our smMIP‐based NGS approach provides analysis of both strands of the open reading frame of BRCA1 and BRCA2, enabling the discrimination between real variants and formalin‐induced artefacts. The single molecule tag enables compilation of unique reads leading to a high analytical sensitivity and enabling assessment of the reliability of mutation‐negative results. Multiplex ligation‐dependent probe amplification (MLPA) and Methylation‐specific multiplex ligation‐dependent probe amplification (MS‐MLPA) were used to detect exon deletions of BRCA1 and methylation of the BRCA1 promoter, respectively. Here, we show that this combined approach allows the rapid and reliable detection of both germline and somatic aberrations affecting BRCA1 and BRCA2 in DNA derived from FFPE OCs, enabling improved hereditary cancer risk assessment and clinical treatment of ovarian cancer patients.

show abstract

An international assessment of ovarian cancer incidence and mortality

Cited by 201 publications

References 18 publications

Time Trends of Ovarian Cancer Incidence in China

Time Trends of Ovarian Cancer Incidence in China

Epidemiology of Female Reproductive Cancers in Iran: Results of the Gholestan Population-Based Cancer Registry

NovelBRCA1andBRCA2Tumor Test as Basis for Treatment Decisions and Referral for Genetic Counselling of Patients with Ovarian Carcinomas

Contact Info

Product

Resources

About